PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance

U.S. Markets close in 5 hrs 7 mins

Pfizer Inc. (PFE)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
34.19+0.19 (+0.55%)
As of 10:53AM EDT. Market open.
People also watch
MRKJNJJPMGEINTC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close34.00
Open33.74
Bid0.00 x
Ask0.00 x
Day's Range33.75 - 34.20
52 Week Range29.41 - 37.39
Volume4,406,310
Avg. Volume25,099,672
Market Cap203.58B
Beta1.04
PE Ratio (TTM)29.14
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.76%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com32 minutes ago

    Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All?

    Remember when Bristol-Myers Squibb (BMY) was getting hit so hard that everyone was wondering whether it would find itself acquired by another pharmaceutical, with Pfizer (PFE), Novartis (NVS), Gilead Sciences (GILD), and Roche mentioned as possible buyers? In a note released yesterday, Credit Suisse analyst Vamil Divan and team revisit the possibility of Pfizer taking over Bristol-Myers with their colleagues at the firm's HOLT team...and find that it just might provide "an opportunity for value creation" after all.

  • 3 Big Pharma Stocks You Don't Have to Babysit
    Motley Fool52 minutes ago

    3 Big Pharma Stocks You Don't Have to Babysit

    No tending needed for big pharma stocks Johnson & Johnson, Pfizer, and Novartis.

  • Pfizer Chief Says Government Efforts to Contain Drug Prices Will Backfire
    The Fiscal Times3 hours ago

    Pfizer Chief Says Government Efforts to Contain Drug Prices Will Backfire

    Pfizer Inc., the world’s largest drug manufacturer, is no stranger to the growing controversy over price gouging and anti-competitive practices that have drawn sharp criticism from President Trump and prompted calls for government intervention. Last December, for example, Pfizer and Flynn Pharma Ltd. were hit with record fines totaling more than $110 million in Great Britain after they were found to have conspired to increase prices by as much as 2,600 percent for unbranded versions of the anti-epilepsy drug Epanutin.